• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NanoVibronix Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    9/25/24 5:00:10 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    false 0001326706 0001326706 2024-09-20 2024-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 20, 2024

     

    NanoVibronix, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-36445   01-0801232

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    969 Pruitt Ave, Tyler, Texas 77569

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (914) 233-3004

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NAOV   Nasdaq Capital Market

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Chief Executive Officer

     

    As previously disclosed, NanoVibronix, Inc. (the “Company”) entered into an Employment Agreement, dated January 1, 2022, with Brian Murphy (the “2022 Murphy Agreement”), pursuant to which the parties agreed to have Mr. Murphy continue to serve as Chief Executive Officer of the Company, effective January 1, 2022. On September 20, 2024, the Company entered into a new Employment Agreement with Mr. Murphy (the “2024 Murphy Agreement”), pursuant to which the parties agreed to have Mr. Murphy continue to serve as Chief Executive Officer of the Company, effective September 20, 2024, through August 31, 2025, unless earlier terminated by either party pursuant to the 2024 Murphy Agreement. The 2022 Murphy Agreement terminated upon effectiveness of the 2024 Murphy Agreement.

     

    As consideration for his services as Chief Executive Officer, Mr. Murphy will be entitled to receive (i) an annual base salary of $321,000, less applicable payroll deductions and tax withholdings; (ii) reimbursement of any reasonable and customary, documented out-of-pocket expenses actually incurred by Mr. Murphy in connection with the performance of his services under the 2024 Murphy Agreement; and (iii) an annual bonus of up to $100,000, less applicable payroll deductions and tax withholdings, based on the extent to which Mr. Murphy met performance criteria for the calendar year, as determined by the Company in good faith. Mr. Murphy may also be eligible to receive certain grants of incentive stock options to purchase shares of common stock of the Company.

     

    Either party may terminate the 2024 Murphy Agreement at any time upon ninety (90) days written notice. Upon termination of Mr. Murphy’s employment, the Company shall pay Mr. Murphy (i) any unpaid salary accrued through the date of termination, (ii) any accrued and unpaid vacation or similar pay to which Mr. Murphy is entitled as a matter of law or Company policy, and (iii) any unreimbursed expenses properly incurred prior to the date of termination (the “Murphy Accrued Obligations”).

     

    In the event the Company terminates Mr. Murphy’s employment for cause, the Company shall have no further liability or obligation to Mr. Murphy under the 2024 Murphy Agreement or in connection with Mr. Murphy’s employment, except for the Murphy Accrued Obligations.

     

    The 2024 Murphy Agreement also contains certain standard non-competition, non-solicitation, confidentiality, and assignment of inventions requirements for Mr. Murphy.

     

    The foregoing summary of the 2024 Murphy Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2024 Murphy Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Chief Financial Officer

     

    As previously disclosed, the Company entered into an Employment Agreement, dated January 1, 2022, with Stephen Brown (the “2022 Brown Agreement”), pursuant to which the parties agreed to have Mr. Brown continue to serve as Chief Financial Officer of the Company, effective January 1, 2022. On September 20, 2024, the Company entered into a new Employment Agreement with Stephen Brown (the “2024 Brown Agreement”), pursuant to which the parties agreed to have Mr. Brown continue to serve as Chief Financial Officer of the Company, effective September 20, 2024, through August 31, 2025, unless earlier terminated by either party pursuant to the 2024 Brown Agreement. The 2022 Brown Agreement terminated upon effectiveness of the 2024 Brown Agreement.

     

     

     

     

    As consideration for his services as Chief Financial Officer, Mr. Brown will be entitled to receive (i) an annual base salary of $267,500, less applicable payroll deductions and tax withholdings; (ii) reimbursement of any reasonable and customary, documented out-of-pocket expenses actually incurred by Mr. Brown in connection with the performance of his services under the 2024 Brown Agreement; and (iii) an annual bonus of up to $50,000, less applicable payroll deductions and tax withholdings, based on the extent to which Mr. Brown has met performance criteria for the calendar year, as determined by the Company in good faith. Mr. Brown may also be eligible to receive certain grants of incentive stock options to purchase shares of common stock of the Company.

     

    Either party may terminate the 2024 Brown Agreement at any time upon ninety (90) days written notice. Upon termination of Mr. Brown’s employment, the Company shall pay Mr. Brown (i) any unpaid salary accrued through the date of termination, (ii) any accrued and unpaid vacation or similar pay to which Mr. Brown is entitled as a matter of law or Company policy, and (iii) any unreimbursed expenses properly incurred prior to the date of termination (the “Brown Accrued Obligations”).

     

    In the event the Company terminates Mr. Brown’s employment for cause, the Company shall have no further liability or obligation to Mr. Brown under the 2024 Brown Agreement or in connection with Mr. Brown’s employment, except for the Brown Accrued Obligations.

     

    The 2024 Brown Agreement also contains certain standard non-competition, non-solicitation, confidentiality, and assignment of inventions requirements for Mr. Brown.

     

    The foregoing summary of the 2024 Brown Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2024 Brown Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Employment Agreement, dated as of September 20, 2024, by and between Brian Murphy and NanoVibronix, Inc.
    10.2   Employment Agreement, dated as of September 20, 2024, by and between Stephen Brown and NanoVibronix, Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 25, 2024 NANOVIBRONIX, Inc.
         
      By: /s/ Stephen Brown
      Name: Stephen Brown
      Title: Chief Financial Officer

     

     

     

     

    Get the next $NAOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    SEC Filings

    View All

    SEC Form 424B3 filed by NanoVibronix Inc.

    424B3 - ENvue Medical, Inc. (0001326706) (Filer)

    12/18/25 5:00:19 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NanoVibronix, Inc. (0001326706) (Filer)

    12/12/25 9:06:28 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form S-3/A filed by NanoVibronix Inc.

    S-3/A - NanoVibronix, Inc. (0001326706) (Filer)

    12/9/25 9:28:07 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Pionati Pellegrino

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:40:32 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Johnson David Ian

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    12/18/25 5:36:25 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Executive Officer Murphy Brian M

    4 - NanoVibronix, Inc. (0001326706) (Issuer)

    1/3/25 4:05:16 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera

    TYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's patent application titled "Feeding Tube with Electromagnetic Sensor and Camera," Application No. 18/199,059. The allowed patent includes 18 claims covering a feeding tube design that combines electromagnetic navigation with an integrated distal-tip camera, enabling both positional guidance and direct visualization during placement. The allowed claims include innovations such

    2/24/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line

    TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke

    1/28/26 9:00:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces CEO Transition

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

    6/4/25 8:38:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

    NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

    12/15/22 4:05:00 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Financials

    Live finance-specific insights

    View All

    NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

    NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

    9/14/22 9:25:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by NanoVibronix Inc.

    SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

    2/14/24 3:45:41 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    2/16/21 3:49:24 PM ET
    $NAOV
    Industrial Specialties
    Health Care